Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti─infective agents to treat serious infections, announced that the US Food and Drug Administration...
Latest articles
[column] Merkdisruptie megatrend (8): Narcisme
Veel merken gaan de komende tijd verdwijnen. Het boek ‘Merkdisruptie’ van Frank Haveman, Jeroen Cremer en Richard Otto, brengt de oorzaken in kaart aan de hand van vijftien megatrends. Op Marketingtribune...
EMA validates Gilead Sciences & Galapagos’ MAA for filgotinib to treat RA
Biopharmaceutical companies, Gilead Sciences and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults
FDA approves novel device to treat symptoms associated with advanced heart failure
The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices...
FDA approves first spinal tether device to treat children with idiopathic scoliosis
The U.S. Food and Drug Administration today approved the first spinal tether device intended to be used in children and adolescents to correct the most common form of scoliosis, called idiopathic scoliosis, that has not...
US FDA approves AbbVie’s oral JAK inhibitor, Rinvoq to treat rheumatoid arthritis
AbbVie, a research─based global bio pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once─daily oral Janus kinase (JAK) inhibitor, for the...
